224 related articles for article (PubMed ID: 2722063)
1. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors.
Kühn W; Kaufmann M; Feichter GE; Rummel HH; Schmid H; Heberling D
Gynecol Oncol; 1989 Jun; 33(3):360-7. PubMed ID: 2722063
[TBL] [Abstract][Full Text] [Related]
2. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.
Friedlander ML; Hedley DW; Swanson C; Russell P
J Clin Oncol; 1988 Feb; 6(2):282-90. PubMed ID: 3276825
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
4. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
5. Cellular DNA content and survival in advanced ovarian carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Renz H; du Bois A; Kiechle-Schwarz M; Pfleiderer A
Cancer; 1994 Nov; 74(9):2509-15. PubMed ID: 7923008
[TBL] [Abstract][Full Text] [Related]
6. Mucinous borderline and malignant tumors of the ovary. A clinicopathologic and DNA ploidy study of 92 cases.
Guerrieri C; Högberg T; Wingren S; Fristedt S; Simonsen E; Boeryd B
Cancer; 1994 Oct; 74(8):2329-40. PubMed ID: 7922984
[TBL] [Abstract][Full Text] [Related]
7. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome.
Demirel D; Laucirica R; Fishman A; Owens RG; Grey MM; Kaplan AL; Ramzy I
Cancer; 1996 Apr; 77(8):1494-500. PubMed ID: 8608534
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage.
Lage JM; Weinberg DS; Huettner PC; Mark SD
Cancer; 1992 Jun; 69(11):2668-75. PubMed ID: 1571896
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric analysis of DNA and cell proliferation in ovarian tumors.
Christov K; Vassilev N
Cancer; 1988 Jan; 61(1):121-5. PubMed ID: 3334938
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of DNA content in epithelial ovarian cancer.
Gajewski WH; Fuller AF; Pastel-Ley C; Flotte TJ; Bell DA
Gynecol Oncol; 1994 Apr; 53(1):5-12. PubMed ID: 8175021
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of nuclear DNA quantification and cyclin A expression in epithelial ovarian carcinoma.
Yoon BS; Kim YT; Kim S; Lee CS; Kim JW; Kim JH; Kim SW; Cho NH
Eur J Obstet Gynecol Reprod Biol; 2008 Jan; 136(1):110-5. PubMed ID: 17157431
[TBL] [Abstract][Full Text] [Related]
12. [Extent of psammoma carcinomas of the ovary--a clinical, DNA flow cytophotometric and morphometric image analysis study].
Kühn W; Feichter GE; Beier K; Rummel HH; Abel U; Kaufmann M
Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):597-604. PubMed ID: 2170226
[TBL] [Abstract][Full Text] [Related]
13. Influence of cellular DNA content on survival in ovarian carcinoma.
Klemi PJ; Joensuu H; Mäenpää J; Kiilholma P
Obstet Gynecol; 1989 Aug; 74(2):200-4. PubMed ID: 2748056
[TBL] [Abstract][Full Text] [Related]
14. Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.
Motohara T; Tashiro H; Miyahara Y; Sakaguchi I; Ohtake H; Katabuchi H
Cancer Sci; 2010 Jun; 101(6):1550-6. PubMed ID: 20384630
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study.
Kaern J; Tropé CG; Kristensen GB; Tveit KM; Pettersen EO
Am J Obstet Gynecol; 1994 Feb; 170(2):479-87. PubMed ID: 8116701
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.
Bakshi N; Rajwanshi A; Patel F; Ganguly NK
Anal Quant Cytol Histol; 1998 Jun; 20(3):215-20. PubMed ID: 9642449
[TBL] [Abstract][Full Text] [Related]
17. Flow and image cytometric DNA ploidy, including 5c exceeding cells, of serous borderline malignant ovarian tumors. Correlation with clinicopathologic characteristics.
Flezar MS; But I; Kavalar R; Us-Krasovec M
Anal Quant Cytol Histol; 2003 Jun; 25(3):139-45. PubMed ID: 12882085
[TBL] [Abstract][Full Text] [Related]
18. Effect of cellular DNA content on the prognosis of epithelial ovarian cancers.
Ozalp S; Yalcin OT; Gulbas Z; Tanir HM; Minsin T
Gynecol Obstet Invest; 2001; 52(2):93-7. PubMed ID: 11586035
[TBL] [Abstract][Full Text] [Related]
19. Flow-cytometric prognostic factors for the survival of patients with ovarian carcinoma: a 5-year follow-up study.
Volm M; Kleine W; Pfleiderer A
Gynecol Oncol; 1989 Oct; 35(1):84-9. PubMed ID: 2792909
[TBL] [Abstract][Full Text] [Related]
20. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary.
Kigawa J; Minagawa Y; Ishihara H; Kanamori Y; Terakawa N
Cancer; 1993 Aug; 72(3):804-8. PubMed ID: 8334634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
